Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.

Abstract excerpt

The discovery that some melanoma tumours harbour mutations in the BRAF gene (e.g. V600E) and the subsequent development of specific BRAF inhibitors have greatly improved the treatment of metastatic melanoma. Resistance of tumour cells to BRAF inhibitors is reduced by the addition of an MEK inhibitor; both BRAF and MEK inhibitors have been reported to produce a variety of dermatological toxic effects. Benign naevi...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Head and Neck Neoplasms
• Share to Imidazoles
• Share to MAP Kinase Kinase Kinases